Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)–positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 7515-7515 ◽  
Author(s):  
D. Kim ◽  
J. K. Lee ◽  
H. S. Park ◽  
K. Kulig ◽  
T. M. Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Anaplastic Lymphoma ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

2012 ◽  
Vol 23 ◽  
pp. xi44
Author(s):  
P.-C. Yang ◽  
R. Salgia ◽  
B. Solomon ◽  
A.T. Shaw ◽  
D.R. Camidge ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Visual Effects ◽  
Anaplastic Lymphoma ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

2019 ◽  
Vol 14 (11) ◽  
pp. S1171-S1172
Author(s):  
T. Leal ◽  
H. Wakelee ◽  
K.L. Reckamp ◽  
A. Chiappori ◽  
G.R. Oxnard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals Systematic Literature Review (SLR) Of Sequencing Of Anaplastic Lymphoma Kinase (ALK) Inhibitors In ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

2018 ◽  
Vol 21 ◽  
pp. S49-S50 ◽  
Author(s):  
SM Barrows ◽  
K Wright ◽  
C Copley-Merriman ◽  
JA Kaye ◽  
MD Chioda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Literature Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Anaplastic Lymphoma ◽  
Alk Positive

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS9115-TPS9115 ◽  
Author(s):  
Leora Horn ◽  
Yi-Long Wu ◽  
Martin Reck ◽  
Heather A. Wakelee ◽  
Chris Liang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Randomized Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
Phase 3 ◽  
Anaplastic Lymphoma ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals PD.1.03 Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data

2018 ◽  
Vol 13 (9) ◽  
pp. S156
Author(s):  
T. Leal ◽  
H. Wakelee ◽  
K. Reckamp ◽  
S. Waqar ◽  
S. Patel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals P1.03-010 Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (11) ◽  
pp. S1954
Author(s):  
R. Imase ◽  
S. Endo ◽  
Y. Sasahara ◽  
T. Shinmura ◽  
T. Ozawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Small Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Kinase Inhibitors ◽  
Small Cell ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document